Verily Life Sciences
269 E Grand Avenue
South San Francisco
California
94080
United States
Website: https://www.verily.com/
Email: info@verily.com
About Verily Life Sciences
Launched in 2015, Verily is a subsidiary of Alphabet focused on life sciences and healthcare. Verily’s mission is to make the world’s health data useful so that people enjoy longer and healthier lives. Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. Verily partners with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale.
Introducing Verily
64 articles with Verily Life Sciences
-
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
5/21/2019
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation
-
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
-
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
-
Verily Announces $1 Billion Investment Round to Fund Growth and Innovation
1/3/2019
Verily, an Alphabet company, today announced a $1 billion investment round, led by Silver Lake, as it advances plans on business strategies that are additive and complementary to its current life sciences portfolio.
-
In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.
-
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
-
CLSA Names Pantheon DiNA Award Winners
10/9/2018
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association. -
Investor Enthusiasm About Liquid Biopsies Drives Guardant Health IPO to $1.59 Billion Valuation
10/5/2018
Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO). -
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
-
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
-
Verily will team up with San Diego-based ResMed, a company that specializes in the treatment of sleep disorders, to launch a new joint business venture to address sleep apnea and other sleeping disorders.
-
ResMed, Verily to Form Joint Venture to Help Reach Millions of Untreated Sleep Apnea Sufferers
7/11/2018
ResMed today announced their agreement to form a new joint venture.
-
It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.
-
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
-
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
-
The two companies will use Verity’s Immunoscape platform to profile the molecular characteristics of inflammatory diseases.
-
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
4/30/2018
Gilead Sciences, Inc. and Verily Life Sciences LLC announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases.
-
Glytec Integrates With Onduo Virtual Diabetes Clinic
11/29/2017
The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.